Worth reading
81Important
Scored from 2 of 5 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
37
Hundred millions of yenWording
Conditional
How definitive the wording is.This transaction
Sale of sharesCounterpartyVAROPreem AB
Disclosing companyHARIMA CHEMICALS GROUP,INC.
Execution Date / Effective DateThe sale had been completed as of the disclosure date of 10 July 2026
Target company
Location Sweden
Consideration and expenses
Type of ConsiderationCash
Amount of extraordinary income (loss)Gain on sale of shares in an affiliated company: ¥3.7 billion (estimated amount), expected to be recognized as extraordinary income in the third quarter of the fiscal year ending March 2027
Impact on Business Performance
A gain on the sale of shares in an affiliated company of ¥3.7 billion (estimated amount) is expected to be recognized as extraordinary income in the third quarter of the fiscal year ending March 2027
Procedures and assumptions
Conditions Precedent to ExecutionReceipt of the sale proceeds
| Item | Details |
|---|---|
| Transaction name | Sale of shares |
| Counterparty name | VAROPreem AB |
| Name of the Subject Company | SunPine AB |
| Location of the Subject Company | Sweden |
| Type of Consideration | Cash |
| Amount of extraordinary income (loss) | Gain on sale of shares in an affiliated company: ¥3.7 billion (estimated amount), expected to be recognized as extraordinary income in the third quarter of the fiscal year ending March 2027 |
| Impact on Business Performance | A gain on the sale of shares in an affiliated company of ¥3.7 billion (estimated amount) is expected to be recognized as extraordinary income in the third quarter of the fiscal year ending March 2027 |
| Execution Date / Effective Date | The sale had been completed as of the disclosure date of 10 July 2026 |
| Conditions Precedent to Execution | Receipt of the sale proceeds |
Items this document does not state (23)
Business Description of the Subject CompanyCapital Stock of the Subject CompanyDate of Establishment of the Subject CompanyNet Sales of the Subject CompanyOperating Profit of the Subject CompanyNet Income of the Subject CompanyNet Assets of the Subject CompanyAcquisition priceExpenses other than the acquisition priceMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodNumber of shares acquiredVoting rights ownership percentageFunding arrangementsGoodwill amountDate of board resolutionContract DateValuation methodologyIndependent valuation institutionSpecial CommitteeManagement structure after acquisition
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The proceeds from the sale of the shares will be used to fund capital investment in growth areas and improve the Company’s financial position through debt reduction.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.